Trials / Active Not Recruiting
Active Not RecruitingNCT07313813
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate how fasting and stopping the use of Dulaglutide (LY2189265) affect the amount of food and drink that stays in your stomach after a meal. Ultrasound devices will be used to check the stomach content after a test meal. The study can last approximately 28 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dulaglutide | Administered SC |
Timeline
- Start date
- 2025-12-29
- Primary completion
- 2026-08-01
- Completion
- 2026-08-01
- First posted
- 2026-01-02
- Last updated
- 2026-04-16
Locations
1 site across 1 country: Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07313813. Inclusion in this directory is not an endorsement.